IP Library Patent Application 11824517
Patent Application
App. No. 11/824,517

Composite device for the repair or regeneration of tissue

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/824,517
Abstract

The present invention is directed to composite devices comprising a tissue-engineering scaffold and an anionic polysaccharide/structural protein coating. The composite devices are useful for the reparation and regeneration of tissue, particularly in the treatment of chronic wounds.

Claims (24)

1 . A composite device for the treatment of chronic wounds comprising, a tissue-engineering scaffold and an anionic polysaccharide/structural protein coating, wherein said tissue-engineering scaffold is a biocompatible, biodegradable polymer and said anionic polysaccharide is a mucopolysaccharide or polycarboxylate.

2 . The composite device of claim 1 , wherein said scaffold is selected from the group consisting of sponges, foams, perforated films and textiles.

3 . The composite device of claim 2 , wherein said scaffold is a textile selected from the group consisting of weaves, knits, braids, meshes and nonwovens.

4 . The composite device of claim 3 , wherein said scaffold is a nonwoven comprising a copolymer of glycolide and lactide.

5 . The composite device of claim 3 , wherein said scaffold is a nonwoven comprising a copolymer of glycolide and lactide having a mole ratio of glycolide to lactide of about 90:10.

6 . The composite device of claim 2 , wherein said scaffold is a foam comprising an elastomeric copolymer.

7 . The composite device of claim 6 , wherein said elastomeric copolymer comprises epsilon-caprolactone and glycolide.

8 . The composite device of claim 7 , wherein said elastomeric copolymer comprises a mole ratio of epsilon-caprolactone to glycolide of from about 30:70 to about 70:30.

9 . The composite device of claim 1 , wherein said anionic polysaccharide is selected from the group consisting of heparin, hyaluronic acid, heparan sulphate, chondroitin sulphate, alginates, oxidized regenerated cellulose and oxidized cellulose.

10 . The composite device of claim 1 , wherein said anionic polysaccharide is selected from the group consisting of oxidized regenerated cellulose, oxidized cellulose, hyaluronic acid and chondroitin sulphate.

11 . The composite device of claim 1 , wherein said anionic polysaccharide is oxidized regenerated cellulose.

12 . The composite device of claim 1 , wherein said structural protein is selected from the group consisting of collagen, fibrin, fibronectin and laminin.

13 . The composite device of claim 1 , wherein said structural protein is collagen.

14 . The composite device of claim 1 , wherein said anionic polysaccharide/structural protein has a mole ratio of anionic polysaccharide to structural protein from about 10:90 to about 90:10.

15 . The composite device of claim 1 , wherein said scaffold is a foam comprising an elastomeric copolymer of epsilon-caprolactone and glycolide having a mole ratio of epsilon-caprolactone to glycolide from about 35:65 to about 65:35, and said anionic polysaccharide/structural protein coating is oxidized regenerated cellulose/collagen having a mole ratio from about 10:90 to about 90:10.

16 . The composite device of claim 1 , wherein said scaffold is a foam comprising an elastomeric copolymer of epsilon-caprolactone and glycolide having a mole ratio of epsilon-caprolactone to glycolide of about 35:65, and said anionic polysaccharide/structural protein coating is oxidized regenerated cellulose/collagen having a mole ratio of about 45:55.

17 . The composite device of claim 1 , wherein said scaffold is a nonwoven comprising a copolymer of glycolide and lactide having a mole ratio of about 90:10, and said anionic polysaccharide/structural protein coating is oxidized regenerated cellulose/collagen having a mole ratio of about 45:55.

18 . A method of treating a wound comprising,

a) contacting a wound with one or more composite devices, wherein said device(s) comprise a biocompatible, biodegradable tissue-engineering scaffold having an anionic polysaccharide/structural protein coating,

b) allowing said devices and said wound to remain in contact with each other, and

c) covering or closing said wound,

wherein said wound is treated.

19 . A kit comprising, a sterile composite device of claim 1 .

20 . The composite device of claim 1 , wherein said device is capable of increasing the presence of activated macrophages in said wound.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2013
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ENDO-SURGERY, INC.
Reel/Frame 029595/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ETHICON ENDO-SURGERY, INC.
Reel/Frame 029496/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INC.
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026286/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2009
From: BROWN, LAURA J.; PANOZZO, MARY F.; WARD, JAMES J.; GOSIEWSKA, ANNA; MARSDEN, DONALD CHRISTOPHER
To: ETHICON, INC.
Reel/Frame 022263/0396 →